By a News Reporter-Staff News Editor at Drug Week A patent application by the inventor MISRA, Srikumar, filed on August 31, 2016, was made available online on March 8, 2018, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application has not been assigned to a company or institution. "The plan
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors CHANDRASHEKHAR, Kocherlakota; NAGARAJU, Banda, filed on February 15, 2016, was made available online on March 8, 2018, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Leiutis Pharm
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventor Bishop, Gail, filed on March 11, 2016, was made available online on March 8, 2018, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to University of Iowa Research Foundation. "Currentl
The U.S. Department of Health and Human Services' Food and Drug Administration announced that it expects to award up to two cooperative agreements for a three-dimensional approach for modeling nasal mucociliary clearance via computational fluid dynamics. This funding opportunity uses the research project- cooperative agreements mechanism.
Pune, India 03/22/2018 A biosimilar is a biologic medical product which is almost an identical copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original "innovator" products, and can be manufactured when the original product's patent expires. Reference to the innovator pr
ABU DHABI, 23rd March, 2018 Healthcare experts, who gathered in Abu Dhabi to attend the first American Association for Clinical Chemistry, AACC Middle East Conference, said that laboratory automation has increased the productivity and efficiency of clinical laboratories while highlighting the need for improved communication between physicians and
Global Radio pharmaceutical Information, by types by end users- Forecast to 2022. According to a recent study report published by the Market Research Future, the Global Radio Pharmaceutical Market is expected to gain eminence over the forecast period. According to the World Cancer Research Fund International, in 2015, cancer was responsible for 8.8
Albany, NY 03/22/2018 The digital age has certainly evolved and the new generation is now empowered and driven by the latest technology. 3 D technology is one of them and the fastest growing markets in the world. The 3 D imaging market is an outcome of the traditional diagnostic imaging market. 3 D systems in association with doctors, health
Valley Cottage, NY 03/23/2018 Future Market Insights presents pertinent insights and a revised forecast of the global 3 D printed medical devices market in its published report titled' 3 D Printed Medical Devices Market ": Global Industry Analysis and Opportunity Assessment'. The global 3 D printed medical devices market is expected to expand
AbbVie, a global research and development-based biopharmaceutical company, today announced that after consulting with the U.S. Food and Drug Administration, it will not seek accelerated approval for Rova-T in third-line relapsed/refractory small cell lung cancer based on magnitude of effect across multiple parameters in this single-arm study.
Shares cratered on the terse release, free falling 12% and wiping more than $20 billion off its market cap, which started the day at $178 billion. So with an IRC assessment at 16%, AbbVie is well behind the 8 ball, with the FDA chilling talk of an accelerated approval despite the fact that there are no approved options. AbbVie paid $5.8 billion in
Baltimore, Maryland- Massachusetts- based medical device manufacturer Alere Inc. and its subsidiary Alere San Diego have agreed to pay the United States $33.2 million to resolve allegations that Alere caused hospitals to submit false claims to Medicare and other federal healthcare programs relating to the use of materially unreliable point-of-care.
On March 23, 2018, AMAG Pharmaceuticals, Inc. and Sandoz Inc. entered a stipulation of dismissal, in the United States District Court for the District of New Jersey, pursuant to a settlement agreement, that dismisses and resolves the U.S. patent litigation related to the Company's Feraheme, 30 mg/mL, 17 mL single dose vials, for intravenous use.
AMAG PHARMACEUTICALS,INC. (NASDAQ:AMAG) Files An 8-K Regulation FD DisclosureItem 7.01 Regulation FD. On March 23, 2018, AMAG Pharmaceuticals, Inc. (AMAG or the Company) and Sandoz Inc. entered a stipulation of dismissal, in the United States District Court for the District of New Jersey, to a settlement agreement, that dismisses and re
Valley Cottage, NY 03/23/2018 Future Market Insights delivers key insights and presents a revised forecast of the global ambulatory surgical centres market for a 10 year period from 2017 to 2027 in the report titled "Ambulatory Surgical Centres Market: Global Industry Analysis 2012 2016 and Opportunity Assessment 2017 2027." The revisio
Amgen and Allergan plc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the marketing authorization of ABP 980, a biosimilar to Herceptin . ABP 980 has been recommended for approval for the treatment of the same three types of cancer as Herceptin is appr
Amgen today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion to include a new indication in the Repatha label for adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels. "We welcome the CHMP's positiv
THOUSAND OAKS- Amgen and Allergan plc. announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the marketing authorization of ABP 980, a biosimilar to Herceptin. Amgen and Allergan are collaborating on the development and commercialization of four oncology biosimilars.
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a trademark application has been made for "PERFORM PATIENT EVALUATION RESOURCES FOR OPIOID RISK MANAGEMENT" by Alan L. Koller, representing Purdue Pharma. The owner/registrar information for this application is:
ARCA biopharma, a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the year ended December 31, 2017. Michael Bristow, ARCA s President and Chief Executive Officer. We reported top-line Phase 2 B results for the GENETI
Array BioPharma Inc. today announced that detailed results of its pivotal Phase 3 COLUMBUS trial for the treatment of patients with BRAF-mutant advanced, unresectable or metastatic melanoma were published in The Lancet Oncology.
AstraZeneca plc said the European Commission approved its MAA for Lokelma sodium zirconium cyclosilicate to treat hyperkalemia in adults. In March 2017, AZ received its second complete response letter from FDA for the drug following an FDA inspection of a manufacturing facility. The company expects a decision this half from FDA on a resubmitted NDA
AstraZeneca and MedImmune, its global biologics research and development arm, today announced an updated timeline for the final analysis of the Phase III MYSTIC trial of Imfinzi as monotherapy and in combination with tremelimumab, versus platinum-based standard-of-care chemotherapy in previously-untreated patients with metastatic 1st- line...
Auris Health, Inc., formerly known as Auris Surgical Robotics, Inc., today announced U.S. Food and Drug Administration clearance of the company s Monarch? Platform, ushering in a new era of medical intervention. Founded and led by surgical robotics pioneer Frederic Moll, M.D., Auris has raised more than $500 million in equity capital from lead
The study of "2018 Market Research Report on Global Brain Health Supplements Industry" provides the market size information, In-Depth Analysis along with Competitive Insights and Segmentation.